| scholarly article | Q13442814 |
| P2093 | author name string | J Adams | |
| K C Anderson | |||
| P Richardson | |||
| P J Elliott | |||
| D Chauhan | |||
| T Hideshima | |||
| V J Palombella | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple myeloma | Q467635 |
| multiple drug resistance | Q643839 | ||
| drug resistance | Q12147416 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 3071-3076 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells | |
| P478 | volume | 61 |
| Q37164347 | A Bowman-Birk inhibitor induces apoptosis in human breast adenocarcinoma through mitochondrial impairment and oxidative damage following proteasome 20S inhibition |
| Q41869899 | A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma |
| Q92190940 | A High-Throughput Assay for Monitoring Ubiquitination in Real Time |
| Q37259815 | A comparative genomic approach for identifying synthetic lethal interactions in human cancer |
| Q33843095 | A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. |
| Q27329429 | A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease |
| Q33412684 | A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma |
| Q33391795 | A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma |
| Q40287113 | A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia |
| Q35737769 | A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease |
| Q36037229 | A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma |
| Q33367833 | A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma |
| Q41879053 | A rare entity in multiple myeloma: six nerve paralysis |
| Q36822868 | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
| Q36075303 | A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice |
| Q40048204 | A stressful life (or death): combinatorial proteotoxic approaches to cancer-selective therapeutic vulnerability |
| Q38701979 | A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer. |
| Q42943366 | ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. |
| Q34245549 | Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology |
| Q90474833 | Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways |
| Q26849940 | Advances in the understanding of mechanisms and therapeutic use of bortezomib |
| Q37705002 | Advances in treatment for relapses and refractory multiple myeloma |
| Q41943563 | Altered discharges of spinal neurons parallel the behavioral phenotype shown by rats with bortezomib related chemotherapy induced peripheral neuropathy |
| Q37320140 | An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo |
| Q34291281 | An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib |
| Q35759368 | An update of novel therapeutic approaches for multiple myeloma |
| Q89480520 | Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2 |
| Q92831733 | Angiogenesis in cutaneous T-cell lymphoma - proteomic approaches |
| Q37271048 | Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma |
| Q35539175 | Anticancer drug bortezomib increases interleukin-8 expression in human monocytes |
| Q35251058 | Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101 |
| Q35052044 | Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors |
| Q38174398 | Antiviral strategies for hepatitis E virus |
| Q36255777 | Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate |
| Q38122624 | Association of response endpoints with survival outcomes in multiple myeloma |
| Q39698910 | Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma |
| Q24670297 | Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo |
| Q47669883 | BAFF is involved in macrophage-induced bortezomib resistance in myeloma. |
| Q34551213 | BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein |
| Q37467249 | BU-32: a novel proteasome inhibitor for breast cancer |
| Q30952817 | Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells |
| Q34478543 | Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model |
| Q38021040 | Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies |
| Q37201984 | Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications |
| Q39310876 | Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells |
| Q28481321 | Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells |
| Q35678932 | Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options |
| Q33379044 | Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma |
| Q41932078 | Bortezomib Alone and in Combination With Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female Nude Mice |
| Q36378038 | Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity |
| Q89834625 | Bortezomib Treatment Modulates Autophagy in Multiple Myeloma |
| Q35836881 | Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives |
| Q37702765 | Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain CD8+T cell antitumor function. |
| Q38650700 | Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. |
| Q33394873 | Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma |
| Q35828762 | Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications |
| Q93144918 | Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later |
| Q33382441 | Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: a single-center experience |
| Q34418462 | Bortezomib in the management of multiple myeloma. |
| Q36445921 | Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia |
| Q33989444 | Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway |
| Q33747277 | Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. |
| Q36098835 | Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells |
| Q37291635 | Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells |
| Q39271580 | Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis |
| Q38909786 | Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells |
| Q47693664 | Bortezomib inhibits proliferation, migration, and TGF-β1-induced epithelial-mesenchymal transition of RPE cells |
| Q35800649 | Bortezomib inhibits the survival and proliferation of bone marrow stromal cells |
| Q42959495 | Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis |
| Q37160844 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway |
| Q33772264 | Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma. |
| Q33648344 | Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma |
| Q34786865 | Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway |
| Q39065872 | Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial |
| Q37009725 | Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study |
| Q42256076 | Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study |
| Q34079116 | Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors |
| Q38787837 | Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells |
| Q36667443 | Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study |
| Q34980952 | Bortezomib: a review of its use in patients with multiple myeloma |
| Q33400724 | Bortezomib: the evidence of its clinical impact in multiple myeloma. |
| Q42717405 | Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells |
| Q38062038 | Can we change the disease biology of multiple myeloma? |
| Q37058267 | Cancer prevention and therapy through the modulation of the tumor microenvironment |
| Q35005087 | Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models |
| Q35067995 | Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells |
| Q35868965 | Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy |
| Q27663486 | Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit |
| Q39702665 | Characterization of bortezomib-adapted I-45 mesothelioma cells |
| Q88687685 | Characterization of carfilzomib-resistant non-small cell lung cancer cell lines |
| Q28482928 | Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death |
| Q47137683 | Chromosomal instability and acquired drug resistance in multiple myeloma |
| Q33371639 | Chronic graft-versus-host disease: Pathogenesis and clinical management. |
| Q38895976 | Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma |
| Q88868446 | Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib |
| Q28080999 | Clinical use of proteasome inhibitors in the treatment of multiple myeloma |
| Q37271700 | Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment |
| Q36407209 | Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma |
| Q90228230 | Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes |
| Q93541751 | Communication between bone marrow niches in normal bone marrow function and during hemopathies progression |
| Q88666891 | Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease |
| Q41854251 | Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy. |
| Q28478842 | Control of Kaposi's sarcoma-associated herpesvirus reactivation induced by multiple signals |
| Q36353641 | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
| Q37223850 | Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model |
| Q26740444 | Current Trends of Renal Impairment in Multiple Myeloma |
| Q37738476 | Current status of bortezomib in the treatment of multiple myeloma |
| Q26825417 | DangER: protein ovERload. Targeting protein degradation to treat myeloma |
| Q36577080 | David and Goliath: chemical perturbation of eukaryotes by bacteria |
| Q38075795 | Development of Proteasome Inhibitors as Therapeutic Drugs |
| Q43036378 | Development of Small Molecular Proteasome Inhibitors Using a Caenorhabditis elegans Screen. |
| Q36178493 | Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. |
| Q33453188 | Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells |
| Q38627306 | Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses |
| Q36349396 | Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study |
| Q37613621 | Downregulation of Mcl-1 has anti-inflammatory pro-resolution effects and enhances bacterial clearance from the lung |
| Q51504147 | Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. |
| Q26752823 | Drugging the undruggables: exploring the ubiquitin system for drug development |
| Q35741406 | Dysregulation of the Transforming Growth Factor β Pathway in Induced Pluripotent Stem Cells Generated from Patients with Diamond Blackfan Anemia. |
| Q24616455 | EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment |
| Q64056370 | Early Steps in Herpes Simplex Virus Infection Blocked by a Proteasome Inhibitor |
| Q34301113 | Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro |
| Q38089497 | Efficacy of bortezomib as first-line treatment for patients with multiple myeloma |
| Q34059058 | Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma |
| Q33289791 | Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison |
| Q38949914 | Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. |
| Q39107032 | Efficient synthesis of boron-containing α-acyloxyamide analogs via microwave irradiation. |
| Q41370609 | Emerging Roles of Osteoclasts in the Modulation of Bone Microenvironment and Immune Suppression in Multiple Myeloma |
| Q83402616 | Emerging therapies for multiple myeloma |
| Q35825522 | Emerging therapies in hematopoietic stem cell transplantation |
| Q37457302 | Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib |
| Q37698248 | Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. |
| Q37357390 | Endoplasmic reticulum stress-induced cell death mediated by the proteasome |
| Q33863563 | Enzymatic blockade of the ubiquitin-proteasome pathway |
| Q45784186 | Evidence for the Critical Roles of NF-κB p65 and Specificity Proteins in the Apoptosis-Inducing Activity of Proteasome Inhibitors in Leukemia Cells |
| Q36012354 | Evolving treatment strategies for myeloma |
| Q28535634 | Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy |
| Q37688848 | Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors |
| Q36204796 | FOXP3-miR-146-NF-κB Axis and Therapy for Precancerous Lesions in Prostate |
| Q34642317 | Failure of amino acid homeostasis causes cell death following proteasome inhibition. |
| Q36615199 | Flavones induce neutrophil apoptosis by down-regulation of Mcl-1 via a proteasomal-dependent pathway |
| Q28533949 | From bench to bedside: lessons learned in translating preclinical studies in cancer drug development |
| Q37028598 | From the bench to the bedside: emerging new treatments in multiple myeloma |
| Q38172300 | Future agents and treatment directions in multiple myeloma |
| Q42324031 | GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death |
| Q45229028 | Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system |
| Q35828463 | Green tea polyphenols as a natural tumour cell proteasome inhibitor |
| Q47114002 | HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer |
| Q40408326 | Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. |
| Q93541719 | Histone deacetylase inhibitors in multiple myeloma |
| Q36309469 | Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress |
| Q38097867 | Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. |
| Q34598755 | IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis |
| Q36413454 | IKK inhibition increases bortezomib effectiveness in ovarian cancer |
| Q37688677 | IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells |
| Q33569809 | IKKβ links vascular inflammation to obesity and atherosclerosis |
| Q39432161 | Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome |
| Q33479917 | Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance |
| Q37373624 | Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors |
| Q35240656 | Immediate early response gene X-1, a potential prognostic biomarker in cancers |
| Q34666924 | Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism |
| Q35167162 | In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells |
| Q39631346 | In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines |
| Q34501627 | In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib |
| Q27675903 | Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites |
| Q35586471 | Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells |
| Q36014687 | Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma |
| Q36038899 | Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors |
| Q48505281 | Infliction of proteotoxic stresses by impairment of the unfolded protein response or proteasomal inhibition as a therapeutic strategy for mast cell leukemia |
| Q93003319 | Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability |
| Q31028788 | Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. |
| Q36546004 | Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance |
| Q45074664 | Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity |
| Q39990380 | Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells |
| Q34332019 | Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib |
| Q36465296 | Inhibition of proteasome activity by the dietary flavonoid apigenin is associated with growth inhibition in cultured breast cancer cells and xenografts |
| Q92234424 | Inhibition of the FAD containing ER oxidoreductin 1 (Ero1) protein by EN-460 as a strategy for treatment of multiple myeloma |
| Q28542684 | Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737 |
| Q38878577 | Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma |
| Q40561962 | Innovative strategies in lymphoma therapy |
| Q36902184 | Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib |
| Q37098847 | Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity |
| Q42357210 | Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells |
| Q36226588 | Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy |
| Q40979196 | Involvement of the TGFβ1/Smad2/MMP3 signaling pathway in SB431542-induced inhibition of cell invasion in multiple myeloma RPMI 8226 cells |
| Q24570128 | Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls |
| Q35900943 | JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells |
| Q35776414 | KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells |
| Q37750106 | Kidney disease associated with plasma cell dyscrasias |
| Q38844648 | Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in adriamycin-resistant human glioma cells. |
| Q33389111 | Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma |
| Q35962054 | Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells |
| Q37289335 | Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner |
| Q27930325 | Loss of a 20S proteasome activator in Saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of action |
| Q42372836 | Low Neurotoxicity of ONX-0914 Supports the Idea of Specific Immunoproteasome Inhibition as a Side-Effect-Limiting, Therapeutic Strategy. |
| Q33758880 | MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma |
| Q64948286 | MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1α and H1.2. |
| Q58085077 | Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells |
| Q36092102 | Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells |
| Q26738970 | Maintaining Genome Stability in Defiance of Mitotic DNA Damage |
| Q35440568 | Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer |
| Q37954600 | Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma |
| Q41770950 | Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma |
| Q35178969 | MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. |
| Q36602853 | MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies |
| Q35849287 | Microscale functional cytomics for studying hematologic cancers |
| Q51311518 | Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs. |
| Q36498784 | Model of translational cancer research in multiple myeloma |
| Q78299664 | Molecular aspects of multiple myeloma |
| Q34608271 | Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib |
| Q37161937 | Molecular mechanisms of green tea polyphenols |
| Q34393832 | Molecular sequelae of proteasome inhibition in human multiple myeloma cells |
| Q33386405 | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma |
| Q89682913 | Multiple Myeloma: Available Therapies and Causes of Drug Resistance |
| Q83411634 | Multiple myeloma |
| Q24655964 | Multiple myeloma |
| Q37365560 | Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. |
| Q37031914 | Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma |
| Q35551882 | NF-κB signaling mediates acquired resistance after PARP inhibition |
| Q35828472 | Natural compounds with proteasome inhibitory activity for cancer prevention and treatment |
| Q51249475 | New Peptidomimetic Boronates for Selective Inhibition of the Chymotrypsin-like Activity of the 26S Proteasome. |
| Q36822739 | New applications of old metal-binding drugs in the treatment of human cancer |
| Q79423983 | New frontiers in the treatment of multiple myeloma |
| Q42237173 | New inhibitor targeting human transcription factor HSF1: effects on the heat shock response and tumor cell survival |
| Q36986576 | New therapies in multiple myeloma. |
| Q88357671 | Next-generation proteasome inhibitors for cancer therapy |
| Q35915829 | Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors. |
| Q34996147 | Novel biologically based therapies for multiple myeloma |
| Q92334100 | Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells |
| Q37298880 | Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment |
| Q26773246 | Novel strategies to target the ubiquitin proteasome system in multiple myeloma |
| Q36161365 | Novel therapeutic agents for cutaneous T-Cell lymphoma |
| Q36449521 | Novel treatment approaches for patients with relapsed and refractory multiple myeloma |
| Q38977283 | Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition |
| Q34552894 | Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy |
| Q39210001 | PDK1 inhibition is a novel therapeutic target in multiple myeloma |
| Q28484680 | PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells |
| Q37737793 | PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment |
| Q42821645 | PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo |
| Q34050681 | PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL |
| Q40328451 | Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells |
| Q37308719 | Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. |
| Q47955863 | Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma |
| Q40550633 | Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model |
| Q36404114 | Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice |
| Q33388541 | Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma |
| Q86991759 | Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma |
| Q33717413 | Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach |
| Q34225158 | Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group |
| Q34376187 | Physiological levels of ATP negatively regulate proteasome function. |
| Q38999733 | Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. |
| Q36384889 | Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma |
| Q24814325 | Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy |
| Q36998210 | Preclinical studies of novel targeted therapies |
| Q39622895 | Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. |
| Q35761070 | Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy |
| Q34608608 | Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. |
| Q33584749 | Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells |
| Q44694137 | Progress and Paradigms in Multiple Myeloma |
| Q35824980 | Progress in myeloma stem cells |
| Q30476988 | Progressively impaired proteasomal capacity during terminal plasma cell differentiation |
| Q42124140 | Prolonged Treatment of Peanut-Allergic Mice with Bortezomib Significantly Reduces Serum Anti-Peanut IgE but Does Not Affect Allergic Symptoms |
| Q42581682 | Promising therapies in multiple myeloma |
| Q36650691 | Protease inhibitors and their peptidomimetic derivatives as potential drugs |
| Q34154200 | Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells |
| Q92921561 | Proteasome Inhibitors for the Treatment of Multiple Myeloma |
| Q89598452 | Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease |
| Q34343036 | Proteasome inhibition and its therapeutic potential in multiple myeloma |
| Q39119033 | Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. |
| Q35005523 | Proteasome inhibition improves diaphragm function in congestive heart failure rats |
| Q37536497 | Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells |
| Q58796147 | Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: Opportunity for combination therapy |
| Q34085747 | Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients |
| Q91792206 | Proteasome inhibition-a new target for brain tumours |
| Q35109750 | Proteasome inhibition: a new anti-inflammatory strategy |
| Q51129826 | Proteasome inhibitor MG132 induces thyroid cancer cell apoptosis by modulating the activity of transcription factor FOXO3a. |
| Q40291997 | Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. |
| Q47140422 | Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. |
| Q36967854 | Proteasome inhibitor, bortezomib, for myeloma and lymphoma |
| Q38202977 | Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma |
| Q33598931 | Proteasome inhibitors in glioblastoma |
| Q34611676 | Proteasome inhibitors in the treatment of multiple myeloma |
| Q40310345 | Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells |
| Q44507288 | Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion |
| Q64979746 | Proteasome inhibitors: structure and function. |
| Q37411350 | Proteasome regulators: activators and inhibitors. |
| Q47161331 | Proteasome-associated deubiquitinases and cancer |
| Q33712077 | Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells |
| Q36234472 | Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity |
| Q41587932 | RSK1 protects P-glycoprotein/ABCB1 against ubiquitin-proteasomal degradation by downregulating the ubiquitin-conjugating enzyme E2 R1 |
| Q26740191 | Redox Homeostasis and Cellular Antioxidant Systems: Crucial Players in Cancer Growth and Therapy |
| Q35874721 | Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington's Disease |
| Q37021647 | Regulation and function of nuclear IκBα in inflammation and cancer |
| Q33587139 | Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage |
| Q24815441 | Regulation of IkappaBalpha expression involves both NF-kappaB and the MAP kinase signaling pathways |
| Q36674720 | Regulation of RIPK3- and RHIM-dependent Necroptosis by the Proteasome |
| Q34633196 | Regulation of apoptosis by the ubiquitin and proteasome pathway. |
| Q64101929 | Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition |
| Q38256553 | Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma |
| Q35643032 | Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. |
| Q34798095 | Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma |
| Q34607063 | Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis. |
| Q39586108 | Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line |
| Q36611288 | Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries |
| Q37230257 | Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. |
| Q40440440 | SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma |
| Q46577984 | Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment |
| Q26740359 | Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? |
| Q38252591 | Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities |
| Q39753695 | Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites |
| Q64055555 | Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary study |
| Q24669938 | Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma |
| Q39883372 | Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition |
| Q99631248 | Serum 20S proteasome levels are associated with disease activity in MPO-ANCA-associated microscopic polyangiitis |
| Q33429980 | Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial |
| Q37211838 | Small compound 6-O-angeloylplenolin induces caspase-dependent apoptosis in human multiple myeloma cells |
| Q28478936 | Small compound 6-O-angeloylplenolin induces mitotic arrest and exhibits therapeutic potentials in multiple myeloma |
| Q33854012 | Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma |
| Q39920373 | Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma |
| Q64077112 | Suppression of the Ubiquitin Pathway by Small Molecule Binding to Ubiquitin Enhances Doxorubicin Sensitivity of the Cancer Cells |
| Q36681767 | Synthesis and Evaluation of Macrocyclic Peptide Aldehydes as Potent and Selective Inhibitors of the 20S Proteasome. |
| Q35538460 | TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities |
| Q53280723 | TRIM proteins and cancer. |
| Q36162690 | Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma |
| Q34480149 | Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death |
| Q52372117 | Targeting IκappaB kinases for cancer therapy. |
| Q35989478 | Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis |
| Q33585280 | Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death |
| Q28272373 | Targeting NF-kappaB in Waldenstrom macroglobulinemia |
| Q40125230 | Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth |
| Q37446828 | Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine |
| Q92382947 | Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling |
| Q39681030 | Targeting integrin-linked kinase increases apoptosis and decreases invasion of myeloma cell lines and inhibits IL-6 and VEGF secretion from BMSCs |
| Q28534151 | Targeting neuroblastoma stem cells with retinoic acid and proteasome inhibitor |
| Q28269674 | Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis |
| Q33384287 | Targeting the UPS as therapy in multiple myeloma |
| Q35778231 | Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. |
| Q87038902 | Targeting the ubiquitin-proteasome system for cancer therapy |
| Q37070437 | Tea polyphenols, their biological effects and potential molecular targets |
| Q35740987 | The 19S proteasomal lid subunit POH1 enhances the transcriptional activation by Mitf in osteoclasts |
| Q35624079 | The 26S proteasome complex: an attractive target for cancer therapy |
| Q36709283 | The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma |
| Q64905989 | The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells. |
| Q35779961 | The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner |
| Q37645630 | The Mechanistic Links Between Proteasome Activity, Aging and Age-related Diseases |
| Q36836686 | The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? |
| Q37689252 | The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). |
| Q33384289 | The UPS: a promising target for breast cancer treatment. |
| Q39686446 | The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state |
| Q52666760 | The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells. |
| Q36598427 | The future in advanced prostate cancer: take your partners or is the last dance for me? |
| Q35444159 | The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies |
| Q39407246 | The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo |
| Q35996498 | The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM |
| Q36216192 | The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. |
| Q42037254 | The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib |
| Q39029195 | The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma |
| Q95650650 | The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges |
| Q24813108 | The proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism |
| Q37034189 | The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo |
| Q36499578 | The proteasome: a novel target for anticancer therapy |
| Q34256126 | The resistance mechanisms of proteasome inhibitor bortezomib |
| Q34316960 | The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma |
| Q36558575 | The role of microenvironment in tumor angiogenesis |
| Q35001441 | The role of proteasome inhibition in nonsmall cell lung cancer |
| Q90093670 | The role of ubiquitination in tumorigenesis and targeted drug discovery |
| Q35540030 | The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma |
| Q35848514 | The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism |
| Q35824929 | The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery |
| Q35836872 | The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention |
| Q53495126 | The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research. |
| Q35097319 | The use of novel agents in the treatment of relapsed and refractory multiple myeloma |
| Q28481010 | Therapeutic trial of metformin and bortezomib in a mouse model of tuberous sclerosis complex (TSC) |
| Q37815035 | Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy |
| Q35291809 | Therapy strategies for multiple myeloma: current status |
| Q94322142 | Three‐drug versus two‐drug induction therapy regimens for patients with transplant‐eligible multiple myeloma |
| Q34148151 | Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen species-mediated signaling pathway and recruitment of CCAAT/enhancer-binding protein delta and CREB-binding protein |
| Q37367298 | Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody |
| Q36115683 | Treatment of myeloma in patients not eligible for transplantation |
| Q36951934 | Treatment strategies in elderly patients with multiple myeloma: current status |
| Q28082910 | Trial Watch: Proteasomal inhibitors for anticancer therapy |
| Q37207049 | Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. |
| Q38265657 | Ubiquitination in disease pathogenesis and treatment |
| Q35905929 | Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib |
| Q34646755 | Utilization of the Eμ-Myc mouse to model heterogeneity of therapeutic response |
| Q35097328 | Waldenstrom macroglobulinemia |
| Q38503345 | When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response |
| Q24630709 | Why bortezomib cannot go with 'green'? |
| Q36216250 | Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells |
| Q35148080 | YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways |
| Q80098830 | [Designer-drugs in tumor treatment] |
| Q87935076 | [Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma] |
| Q33921377 | p21(WAF1/CIP1) upregulation through the stress granule-associated protein CUGBP1 confers resistance to bortezomib-mediated apoptosis |
Search more.